Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis School of Medicine at the Kidney Cancer Association International Meeting, Miami FL November 15, 2019
Paolo Tarantino: Recap of the first 40 years of ADC development / AACR25, ADC development, antibody, cancer, Cancer Discovery, drug conjugates, fight against
Explore the challenges of RAS inhibitor resistance in PDAC. Learn how KRAS mutations affect treatment outcomes.
Discover the impact of PD-1 immunotherapy on MMRd/MSI-H tumors. Learn about breakthrough results from AACR 2025.
Explore the transformative potential of Antibody-Drug Conjugates in targeted cancer treatments and their impact on precision medicine.
Explore the impact of Zongertinib HER2-Mutant NSCLC treatment with a 71% response rate in the latest Beamion LUNG-1 trial.
Get the latest updates from the KEYNOTE-689 study on pembrolizumab and its impact on head and neck squamous cell carcinoma.
Get insights on Anike (Penpulimab-kcqx) NPC’s role in first-line treatment and its benefits for patients with nasopharyngeal carcinoma.
Uncover the groundbreaking insights from the CodeBreaK 300 study on treating chemorefractory KRAS G12C-mutated mCRC.
Get informed about Nivolumab MSI-H Colorectal and its FDA approval. Detailed insights from the CHECKMATE-8HW trial await.
Prepare for Oncology Conferences 2025 to 2027. Join leading meetings such as ASCO and SABCS for the latest in cancer research.
